Group 1 - The company, Zhejiang Xinhengcheng Co., Ltd., has received approval from the China Interbank Market Dealers Association to register and issue debt financing instruments totaling up to 3 billion yuan [1] - The registration for the short-term financing bonds and medium-term notes is valid for two years from the date of the acceptance notice [1] - The company plans to issue its first tranche of technology innovation bonds for the year 2026 on January 30, 2026, with listing and circulation starting on February 3, 2026 [1] Group 2 - The board of directors of the company approved the proposal for debt financing at the 14th meeting of the 9th board on August 26, 2025, and at the second extraordinary general meeting of shareholders on September 12, 2025 [1] - The issuance results and related documents can be found on the China Money website and the Shanghai Clearing House website [1] - The company emphasizes the authenticity, accuracy, and completeness of the information disclosed [2]

浙江新和成股份有限公司 2026 年度第一期科技创新债券发行结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002001 证券简称：新和成 公告编号：2026-004 2025 年 12 月 24 日，公司收到中国银行间市场交易商协会核发的《接受注 册通知书》（中市协注[2025]SCP392 号、中市协注[2025]MTN1264 号），中国 银行间市场交易商协会同意接受公司超短期融资券、中期票据注册，注册自通知 书落款之日起 2 年内有效，在注册有效期内可分期发行。 本次债券发行的有关文件详见中国货币网（www.chinamoney.com.cn）和上 海清算所（www.shclearing.com.cn）网站。 特此公告。 浙江新和成股份有限公司董事会 2026 年 2 月 4 日 浙江新和成股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开的 第九届董事会第十四次会议、2025 年 9 月 12 日召开的 2025 年第二次临时股东 大会审议通过《关于申请注册发行债务融资工具的议案》，同意公司向中国银行 间市场交 ...

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

Group 1: Economic Growth Targets - Multiple provinces, including Shandong, Shaanxi, and Tianjin, have set economic growth targets for 2026, with a focus on the petrochemical industry as a key area of development [1][2][3] - Shandong aims for a 5% year-on-year increase in the added value of the petrochemical industry, with a target for high-end chemical revenue to account for approximately 60% of the sector [1] - Shaanxi plans to establish 12 trillion-level industrial chains and aims for strategic emerging industries to account for over 30% of its industrial output [2] Group 2: Key Projects and Initiatives - Shandong is advancing major projects such as Qilu Petrochemical and the Shandong Times New Energy Battery Base, with a focus on optimizing the petrochemical industry [1] - Shaanxi is developing fine chemicals and launching projects in clean energy and advanced materials, including the construction of hydrogen energy industry clusters [2] - Tianjin is focusing on green petrochemical projects and aims to establish a green chemical new materials base, with significant investments in technology innovation [3] Group 3: Industry Transformation and Sustainability - Shandong is promoting the transformation and upgrading of the petrochemical industry towards green and low-carbon development [1] - Shaanxi emphasizes the need for energy industry stability and the development of functional materials and biodegradable products [2] - Tianjin is committed to enhancing effective demand and improving project execution in the green chemical sector [3]

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...

Investment Rating - The report maintains a positive outlook on the chemical industry, suggesting to focus on leading companies and those experiencing price increases from the bottom [2][3] Core Insights - The chemical market experienced fluctuations, with the Shenwan Chemical Index declining by 0.86%, underperforming the CSI 300 Index by 0.94%. However, price increases were noted in various products, including dyes and para-nitrochlorobenzene, driven by the cancellation of export tax rebates, which accelerated export activities [2] - The AI industry shows strong demand, positively impacting the entire supply chain. Notable performances include ASML's Q4 results, which exceeded expectations, and SK Hynix's Q4 operating profit doubling year-on-year, marking the strongest performance in history [2] - The real estate sector is stabilizing as the "three red lines" policy ends, indicating a healthier market moving forward [2][3] Summary by Sections Chemical Market Overview - The chemical market saw a mixed performance, with the Shenwan Chemical Index down 0.86% while the CSI 300 Index rose 0.08%. The textile chemical products sector led gains with a 14.33% increase [11][12] - Key price movements included a rise in disperse dyes to an average of 19 CNY/kg and reactive dyes to 23 CNY/kg, reflecting a 5.56% and 4.55% increase respectively [3][29] AI Industry Developments - The AI sector is witnessing robust growth, with major players like ByteDance and Alibaba planning to launch new AI models around the Spring Festival, and significant investments in AI and cloud computing expected to rise from 380 billion CNY to 480 billion CNY over the next three years [2][4] Real Estate Sector Changes - The end of the "three red lines" policy is expected to lead to a more stable and resilient real estate market, as risks from the previous cycle are gradually cleared [3][4] Price Trends in Key Chemical Products - The report highlights significant price increases in various chemical products, with disperse dyes and reactive dyes showing notable upward trends due to rising raw material costs and limited supply [29][30] - The report also notes that the PA66 market is experiencing upward pressure, with prices rising to 14,954 CNY/ton, reflecting a 0.48% increase [33][34]

Investment Rating - The industry investment rating is "Overweight," indicating an expected outperformance of the industry index relative to the benchmark by more than 5% over the next six months [66]. Core Insights - The report highlights strong price support from factories, with solid methionine prices rebounding [1]. - The average prices for various chemical products are provided, showing fluctuations in pricing and profitability across different segments [2]. - The report identifies key listed companies in the chemical sector, including Wanhua Chemical, Baofeng Energy, and others [2]. Summary by Sections 2.1 Basic Chemical Index Trends - The report includes a weekly overview of the basic chemical index trends, indicating overall market movements [10]. 2.2 Polyurethane Sector - The average prices for pure MDI, polymer MDI, and TDI are reported as 17,543, 13,864, and 14,085 CNY/ton respectively, with changes of -171, -36, and +110 CNY/ton [2]. - The gross margins for these products are 4,171, 1,493, and 2,363 CNY/ton, reflecting changes of -332, -196, and -15 CNY/ton [2]. 2.3 Oil, Coal, and Olefin Sector - Average prices for ethane, propane, thermal coal, and naphtha are reported as 1,416, 4,349, 520, and 4,074 CNY/ton respectively, with increases of +147, +52, +0, and +171 CNY/ton [2]. - The average price for polyethylene is 7,162 CNY/ton, showing a rise of +62 CNY/ton [2]. - The theoretical profits for ethane cracking, CTO, and naphtha cracking for polyethylene production are reported as 694, 1,438, and -245 CNY/ton, with respective changes of -161, +41, and -127 CNY/ton [2]. 2.4 Coal Chemical Sector - Average prices for synthetic ammonia, urea, DMF, and acetic acid are 2,184, 1,745, 3,962, and 2,579 CNY/ton respectively, with changes of -27, +5, +68, and -21 CNY/ton [2]. - The gross margins for these products are 199, 72, -92, and 445 CNY/ton, reflecting changes of -21, +1, +10, and -8 CNY/ton [2]. 2.5 Animal Nutrition Sector - Average prices for VA, VE, solid methionine, and liquid methionine are reported as 61.5, 55.1, 17.9, and 14.2 CNY/kg respectively, with changes of -0.7, +0.6, +0.3, and +0.0 CNY/kg [2].

消息面上，民政部印发《关于进一步推进民政科技创新的指导意见》，其中提到，广泛应用人形机器 人、脑机接口、人工智能等前沿技术，开展失能失智预防和抗衰老、生活照料和康复护理、精神慰藉和 社会参与促进、安全风险监测和紧急救援、老年宜居环境建设和适老化改造等方面关键技术装备研发。 截至2026年1月30日 10:05，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，海思科领涨 2.62%，新产业上涨1.67%，华润三九上涨0.96%；片仔癀领跌。医疗创新ETF(516820)最新报价0.36元。 规模方面，医疗创新ETF最新规模达18.67亿元，创近1年新高。从资金净流入方面来看，医疗创新ETF 近10天获得连续资金净流入，最高单日获得4182.65万元净流入，合计"吸金"1.86亿元，日均净流入达 1857.56万元。（数据来源：Wind） 招商证券指出，脑机接口技术已从长期学术探索阶段进入产业拐点，在政策与需求双重驱动下，医疗成 为其核心主战场，占全球应用场景的56%；中国脑机接口产业在系统集成与应用落地方面进展显著， 2025年被正式纳入"十五五"规划中的"六大未来产业"，顶层设计与地方支持同步加 ...

Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, with stocks showing mixed results, led by Haikang and Dabo Medical, while Pianzaihuang experienced a decline [1] - The Medical Innovation ETF has seen continuous net inflows over the past 10 days, with a peak single-day net inflow of 41.83 million yuan, totaling 186 million yuan, averaging 18.58 million yuan daily [1] - Huawei Cloud is set to launch the first implementation area of its industry AI "Dream Factory" plan, focusing on smart healthcare, aiming to integrate top medical resources and cutting-edge technology [1] Group 2 - Guojin Securities notes that global pharmaceutical companies have effectively initiated AI platform construction, significantly enhancing efficiency in target discovery, molecular generation, and clinical trial design [2] - The Medical Innovation ETF closely tracks the China Securities Pharmaceutical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies from the pharmaceutical and medical device sectors [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, and Mindray Medical, collectively accounting for 63.75% of the index [2]